

Methodology article

Open Access

## Evaluation of an immunomagnetic separation method to capture *Candida* yeasts cells in blood

Véronique Apaire-Marchais\*<sup>1</sup>, Marie Kempf<sup>2</sup>, Corinne Lefrançois<sup>1</sup>, Agnès Marot<sup>1</sup>, Patricia Licznar<sup>1</sup>, Jane Cottin<sup>1</sup>, Daniel Poulain<sup>3</sup> and Raymond Robert<sup>1</sup>

Address: <sup>1</sup>Groupe d'Etude des Interactions Hôte-Parasite, UPRES EA 3142, UFR des Sciences Pharmaceutiques et d'Ingénierie de la Santé, 16 Bd Daviers, 49045 Angers Cedex, France, <sup>2</sup>CHU, Laboratoire de Parasitologie-Mycologie, 4 rue Larray, 49045 Angers Cedex, France and <sup>3</sup>Inserm U799, Physiopathologie des Candidoses, Faculté de Médecine, Pôle Recherche, 59037 Lille Cedex, France

Email: Véronique Apaire-Marchais\* - veronique.marchais@univ-angers.fr; Marie Kempf - makempf@chu-angers.fr; Corinne Lefrançois - corinne.lefrancois@univ-angers.fr; Agnès Marot - agnes.marot@univ-angers.fr; Patricia Licznar - patricia.licznar@univ-angers.fr; Jane Cottin - jacottin@chu-angers.fr; Daniel Poulain - dpoulain@univ-lille2.fr; Raymond Robert - raymond.robert@univ-angers.fr

\* Corresponding author

Published: 22 September 2008

Received: 19 February 2008

BMC Microbiology 2008, 8:157 doi:10.1186/1471-2180-8-157

Accepted: 22 September 2008

This article is available from: <http://www.biomedcentral.com/1471-2180/8/157>

© 2008 Apaire-Marchais et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** *Candida* species have become the fourth most-frequent cause of nosocomial bloodstream infections in immunocompromised patients. Therefore, rapid identification of pathogenic fungi to species level has been considered critical for treatment. Conventional diagnostic procedures such as blood culture or biochemical tests are lacking both sensitivity and species specificity, so development of rapid diagnostic is essential.

**Results:** An immunomagnetic method involving anti-*Candida* monoclonal antibodies was developed to capture and concentrate in human blood four different species of *Candida* cells responsible for invasive yeast infections. In comparison with an automated blood culture, processing time of immunomagnetic separation is shorter, saving at least 24 hours to obtain colonies before identification.

**Conclusion:** Thus, this easy to use method provides a promising basis for concentrating all *Candida* species in blood to improve sensitivity before identification.

### Background

*Candida* spp. is now the fourth most frequent cause of nosocomial blood-stream infections in critically ill patients and *Candida albicans* is the most prevalent species [1,2]. Prevalence of other species such as *Candida tropicalis*, *Candida glabrata*, *Candida parapsilosis* and *Candida krusei* varies according to clinical conditions [3]. Rapid isolation and identification of pathogenic yeasts to species level is critical for treatment. Conventional diagnostic

procedures, such as blood culture and biochemical tests lack the degree of sensitivity and specificity that would ensure reliable and early diagnosis of invasive *Candida* infections [4,5]. As a consequence, methods based on the amplification and detection of yeast DNA have been developed. Conventional PCR techniques and now real-time PCR assays are performed for specific and rapid detection and identification of fungi from clinical isolates [6]. However, as yeast load is often lower than 10 CFU per

ml of blood, even in patients suffering from invasive yeast infection [7], sensitivity is the major drawback with these techniques. Sensitivity can be improved by coupling PCR method with other methods, such as hybridization assay [8], by using nested [5,9] or by optimising DNA extraction methods [10,11]. However availability of pure DNA without PCR inhibitors is essential. Another approach is to concentrate yeast cells before culture or DNA extraction using techniques such as the immunomagnetic separation method (IMS) where magnetic beads coated with monoclonal antibodies are used to capture yeast cells present in clinical specimens.

The purpose of this study was to evaluate the usefulness of IMS in improving culture yields. The effectiveness of the IMS was determined and the time to obtain colonies of *Candida* species was compared to that of the Bactec Mycosis-IC/F automated blood culture system. Human blood artificially contaminated with *C. albicans*, *C. tropicalis* which are the most frequently strains isolated in candidemia was used. *C. glabrata* and *C. krusei* were also included in the study because of their reduced susceptibility i.e. higher resistance to fluconazole.

## Results and discussion

### Analytical sensitivity of IMS

Percentages of viable yeast cells captured by beads were calculated in relation to counts of viable cells initially present in inoculated blood and expressed for 1 ml of blood (Table 1). It was observed that yeast cells of all strains studied could be recovered by IMS, but with variable recovery rates. 27.5% and 29.1% for the two strains of *C. albicans* (respectively 5575 and ATCC 66396), 38% for the two *C. glabrata* isolates (5511 and 5484) and about 15% for the two *C. tropicalis* isolates (5437 and 5395). It was moreover noted that immunoseparation recovery rates were more variable for *C. krusei* with 10.8% for isolate 5374 and 43.2% for isolate 5481. A possible explanation

for the lower recovery rate of isolate 5374 is that the antigen recognised by Mab 6B3 might have been expressed at lower level in this strain. Nevertheless, IMS appears as an easy method allowing yeast cells immunocapture in less than one hour and colonies of the four *Candida* species tested after 24 h of culture on SDA-C. If IMS is coupled with a culture on chromogenic medium, it can allow the differentiation and presumptive identification of the pathogen within 24 hours. *C. parapsilosis* was not tested because it is not well recognised by the MAb 5B2. The introduction of beads coated with other specific MAbs (i.e. against *C. parapsilosis*) in the mix is expected to result in a technique for concentrating all major pathogenic *Candida* species in blood

### IMS method in comparison with conventional procedures

The IMS method has several advantages over conventional methods: it is easy to use, no special equipment is required, processing time of IMS is shorter.

In our study, with the automated blood culture method, microbial growth could be detected for all strains of *Candida* after an incubation of about 24 h (Table 1). However, the viable colonies needed to perform identification were only obtained after subsequent sub-culturing and this required a further 24-h incubation. Despite efforts made by many investigators, early and rapid diagnosis of systemic yeast infections remains limited. Culture detection of *Candida* species is often delayed or remains negative because of slow or absent growth of yeast isolates from clinical specimens. Blood cultures are positive for fewer than 50% of patients with invasive candidiasis [2,5]. Then, time to obtain colonies is shorter with IMS, saving at least 24 h in comparison with blood culture. Of course, further optimization should seek for best IMS recovery rates to increase its lower limit of detection.

**Table 1: Analytical sensitivity of *Candida* cells capture with IMS method**

Strains	Time (hours) of positive blood culture (mean $\pm$ SD) <sup>a</sup>	CFU/ml in initial contaminated blood	CFU/ml after IMS (mean $\pm$ SD) <sup>a</sup>	Immunocaptured cells (% $\pm$ SD) <sup>ab</sup>
<i>Candida albicans</i> 5575	25.45 $\pm$ 0.59	32	8.8 $\pm$ 0.6	27.5 $\pm$ 1.9
<i>Candida albicans</i> ATCC 66396	25.95 $\pm$ 1.46	6	1.75 $\pm$ 0.3	29.1 $\pm$ 3.8
<i>Candida krusei</i> 5374	22.26 $\pm$ 0.48	30	3.25 $\pm$ 0.5	10.8 $\pm$ 1.7
<i>Candida krusei</i> 5481	16.20 $\pm$ 0.28	40	17.3 $\pm$ 2.5	43.2 $\pm$ 6.2
<i>Candida glabrata</i> 5511	25.05 $\pm$ 0.5	20	7.6 $\pm$ 1.3	38 $\pm$ 6.4
<i>Candida glabrata</i> 5484	25.38 $\pm$ 0.58	10	3.8 $\pm$ 0.6	38 $\pm$ 6.3
<i>Candida tropicalis</i> 5437	19.02 $\pm$ 0.88	30	4.8 $\pm$ 2.2	16 $\pm$ 3.8
<i>Candida tropicalis</i> 5395	17.51 $\pm$ 0.50	30	4.3 $\pm$ 2.2	14.3 $\pm$ 7.3

<sup>a</sup>calculation of mean and SD is derived from three different experiments

<sup>b</sup>percentage of immunocaptured cells: number of CFU per 1 ml of blood after IMS procedure/number of CFU per 1 ml of blood in initial contaminated blood

CFU: Colony Forming Unit, IMS : ImmunoMagnetic Separation, SD : Standard Deviation

In addition, as demonstrated by other authors, IMS could increase the efficiency of culture or the yield of nucleic acid before a DNA extraction. PCR assays that amplify a highly conserved sequence of the multicopy rRNA gene were developed using DNA extracts from blood specimens. 1 to 5 CFU/ml has been reported as a lower limit for DNA detection by PCR. It was shown that IMS combined with real-time PCR to detect *Plasmodium falciparum* in blood samples [12], or bacteria such as *Escherichia coli* 0157:H7 and *Listeria monocytogenes* in food [13-15], or some viruses (Hepatitis A virus, Norovirus) from environmental samples or food [16,17] is particularly attractive because of the potential for concentrating micro-organisms. Therefore IMS, in conjunction with PCR, considered as one of the most sensitive methods to detect low levels of DNA from pathogens in clinical samples, could be a helpful tool in the diagnosis of candidemia.

## Conclusion

In our study, IMS has been used to capture yeast cells from artificially contaminated human blood using magnetic beads coated with monoclonal antibodies (MAB 5B2 and MAB 6B3) specific to surface antigens of *Candida*. When numbers of CFU ranged from 6 to 40 CFU per ml of blood, IMS allowed immunocapture for the four *Candida* species studied. We are fully aware that it is a study using artificially contaminated blood and another study is now in progress to evaluate what really happens in natural candidemia.

IMS should be useful in order to facilitate the isolation of yeasts from blood saving at least 24 h to obtain colonies before classic identification.

## Methods

### Strains and culture conditions

One ATCC reference strain and 7 *Candida* spp. isolated from clinical samples taken during invasive candidiasis were used: *C. albicans* ATCC 66396, 1 clinical strains of *C. albicans* (5575), two clinical isolates of each of *C. glabrata* (5511, 5484), *C. krusei* (5374, 5481), and *C. tropicalis* (5437, 5395).

Blastoconidia were grown for 24 h at 37°C on Sabouraud-dextrose-agar (SDA) containing chloramphenicol 1 mg/ml (SDA-C). Then 1 colony was suspended in 10 ml of sterile distilled water and the suspension was plated on SDA-C and incubated for 24 h at 37°C. Blastoconidia were removed with a rubber policeman and suspended into 4 ml of sterile distilled water. A dilution of  $0.5 \times 10^{-6}$  of this suspension was prepared in distilled water to obtain a working yeast suspension and then the number of CFU was calculated by plating 100 µl of this fungal dilution on SDA-C.

### Immunomagnetic separation method versus blood culture

Immunomagnetic beads (Estapor® Merck, France) coated with MAB 5B2 or MAB 6B3 (2 mg/ml) were obtained from SR2B (Avrillé, France) [18,19]. MAB 5B2 recognises the predominantly polysaccharidic antigen present on the cell surface of several species of *Candida* (*C. albicans*, *C. glabrata*, *C. tropicalis*) [20]. It is thought that the reactive structures recognised by MAB 5B2 consist of manno-pyranosyl units bound through  $\beta(1-2)$  linkages. MAB 6B3 reacts specifically with a cell wall surface antigen that was found to be expressed by all *C. krusei* strains or isolates [19].

Following the recommendations of the manufacturer of the automated culture system that 3 to 10 ml of blood should be inoculated into Bactec Mycosis-IC/F culture vials (Becton Dickinson, Pont de Claix, France), both methods, IMS and blood culture, were carried out using samples of 4 ml of human blood for consistency.

200 µl samples of the working yeast suspension were added to 10 ml of human blood. For the blood used in this study, our institution has an agreement with the «Etablissement Français du Sang» for research experiments. After shaking, 4 ml of this contaminated blood were inoculated into Bactec fungal medium and microbial growth was detected by fluorescence (Bactec BD9240, Beckton Dickinson). When positive, samples were sub-cultured onto SDA-C medium to obtain colonies.

Separately, for the IMS procedure, 4 ml of the same yeast contaminated blood were lysed using 4 ml of lysis buffer consisting of 5 mM Tris (pH 7.5), 5 mM EDTA (pH 8) and 2% Triton X® 100 by shaking for 5 min at 22°C, in order to lyse erythrocytes and leukocytes and particularly polynuclear neutrophils which could contain intracytoplasmic yeasts. A mix of 50 µl magnetic beads coated with MAB 5B2 and 50 µl of magnetic beads coated with MAB 6B3, were then added. After incubation for 30 min at 22°C in an incubator (Mini Artic, Jouan, France) with gentle agitation on a sample mixer (Dynal, France), the tubes were put in a magnetic device (Dynal) in order to separate the beads from the supernatant which was discarded. The beads were then re-suspended in 100 µl of 5 mM Tris (pH 7.5), 5 mM EDTA (pH 8) before being plated onto SDA-C. After incubation for 24 h at 37°C, number of CFU, corresponding to viable cells which was obtained from 4 ml of blood were expressed per 1 ml of blood. This number of CFU per 1 ml after IMS was compared with the number of CFU determined from 1 ml of blood in the initial contaminated blood. The results were expressed in percentages of immunocaptured cells. All experiments were performed in triplicate.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

JC, VAM and RR conceived the study. RR gave helpful comments regarding the scientific content of the manuscript. VAM co-ordinated the study, supervised the experimental procedures and drafted the manuscript. MK and CL carried out the experiments. AML carried out the monoclonal antibodies production. PL participated in the coordination of the study and contributed to finalise the manuscript. DP contributed in the design of the study and will carry on this work with blood of clinical candidemia. All the authors read and approved the final manuscript.

## Acknowledgements

We wish to thank SR2B, France for providing immunomagnetic beads coated with MAbs 5B2 and 6B3.

## References

- Jarvis WR: **Epidemiology of nosocomial fungal infections, with emphasis on *Candida* species.** *Clin Infect Dis* 1995, **20**:1526-1530.
- Moreira-Oliveira MS, Mikami Y, Miyaji M, Imai T, Schreiber AZ, Moretti ML: **Diagnosis by polymerase chain reaction and blood culture: prospective study in high-risk population and identification of variables associated with development of candidemia.** *Eur J Clin Microbiol Infect Dis* 2005, **24**:721-726.
- Eggimann P, Garbino J, Pittet D: **Epidemiology of *Candida* species infections in critically ill non-immunosuppressed patients.** *Lancet* 2003, **3**:685-702.
- Stevens DA: **Diagnosis of fungal infections: current status.** *J Antimicrobial Chemotherapy* 2002, **49**:11-19.
- White PL, Shetty A, Barnes RA: **Detection of seven *Candida* species using the light cycler system.** *J Med Microbiol* 2003, **52**:229-238.
- Hsu MC, Chen KW, Lo HJ, Chen YC, Liao MH, Lin YH, Li SY: **Species identification of medically important fungi by use of real-time light cycler PCR.** *J Med Microbiol* 2003, **52**:1071-1076.
- Loeffler J, Henke N, Hebart H, Schmidt D, Hagemeyer L, Schumacher U, Einsele H: **Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system.** *J Clin Microbiol* 2000, **38**:586-590.
- Wahyuningsih R, Freisleben HJ, Sonntag HG, Schnitzler P: **Simple and rapid detection of *Candida albicans* DNA in serum by PCR for diagnosis of invasive candidiasis.** *J Clin Microbiol* 2000, **38**:3016-3021.
- Alam FF, Mustafa AS, Khan ZU: **Comparative evaluation of (1-3)- $\beta$ -D-glucan, mannan and anti-mannan antibodies, and *Candida* species-specific snPCR in patients with candidemia.** *BMC Infect Dis* 2007, **7**:103.
- Einsele H, Hebart H, Roller G, Löffler J, Rothenhöfer I, Müller CA, Bowden RA, van Burik JA, Engelhard D, Kanz L, Schumacher U: **Detection and identification of fungal pathogens in blood by using molecular probes.** *J Clin Microbiol* 1997, **35**:1353-1360.
- Loeffler J, Hebart H, Schumacher U, Reitze H, Einsele H: **Comparison of different methods for extraction of DNA of fungal pathogens from cultures and blood.** *J Clin Microbiol* 1997, **35**:3311-3312.
- Seedod N, Lundeberg J, Hedrum A, Aslund L, Holder A, Thaithong S, Uhlen M: **Immuno-magnetic purification to facilitate DNA diagnosis of *Plasmodium falciparum*.** *J Clin Microbiol* 1993, **31**:2715-2719.
- Fu Z, Rogelj S, Kieft TL: **Rapid detection of *Escherichia coli* O157:H7 by immunomagnetic separation and real-time PCR.** *Int J Food Microbiol* 2005, **99**:47-57.
- Gray KM, Bhunia AK: **Specific detection of cytopathogenic *Listeria monocytogenes* using a two-step method of immunoseparation and cytotoxicity analysis.** *J Microbiol Methods* 2005, **60**:259-268.
- Wang L, Li Y, Mustaphai A: **Rapid and simultaneous quantitation of *Escherichia coli* O157:H7, *Salmonella*, and *Shigella* in ground beef by multiplex real-time PCR and immunomagnetic separation.** *J Food Prot* 2007, **7**:1366-1372.
- Abd El Galil KH, El Sökkary MA, Kheira SM, Salazar AM, Yates MV, Chen W, Mulchandani A: **Combined immunomagnetic separation-molecular beacon-reverse transcription-PCR assay for detection of hepatitis A virus from environmental samples.** *Appl Environ Microbiol* 2004, **70**:4371-4374.
- Kobayashi S, Natori K, Takeda N, Sakae K: **Immunomagnetic capture RT-PCR for detection of Norovirus from foods implicated in a foodborne outbreak.** *Microbiol Immunol* 2004, **48**:201-204.
- Hopwood V, Poulain D, Fortier B, Evans G, Vernes A: **A monoclonal antibody to a cell wall component of *Candida albicans*.** *Infect Immun* 1986, **54**:222-227.
- Robert R, Faure O, Carloti A, Lebeau B, Bernard C, Marot-Leblond A, Grillot R, Senet JM: **A monoclonal antibody specific to surface antigen on *Candida krusei*.** *Clin Diagn Lab Immunol* 1998, **5**:121-124.
- Trinel PA, Faille C, Jacquinet PM, Cailliez JC, Poulain D: **Mapping of *Candida albicans* oligomannosidic epitopes by using monoclonal antibodies.** *Infect Immun* 1992, **60**:3845-3851.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

